Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Molecular Biomarkers and Signaling Pathways for Skin Cancer Screening, Diagnosis...
share announcement

Molecular Biomarkers and Signaling Pathways for Skin Cancer Screening, Diagnosis and Therapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".

Deadline for manuscript submissions: closed (28 February 2024) | Viewed by 5054

Special Issue Editors

Dr. Claudio Guarneri

E-Mail Website
Guest Editor
Department of Biomedical and Dental Sciences and Morpho Functional Imaging, University of Messina, Messina, Italy
Interests: Melanoma; Clinical Dermatology; Psoriasis; Treatment; Skin; Cosmetic Surgery; Pathogens; Infection; Diagnosis; Biomarkers; Targeted Therapy; Autoimmune/Autoinflammatory Skin Disease
Special Issues, Collections and Topics in MDPI journals
Dr. Roberta Giuffrida

E-Mail Website
Guest Editor
Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy
Interests: dermato-oncology; melanoma; non-melanoma skin cancer; noninvasive skin imaging; dermoscopy; super-high magnification dermoscopy; basal cell carcinoma; cutaneous squamous cell carcinoma; photodynamic therapy; targeted therapy; immunotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Skin cancer is the most common malignancy worldwide, with rising incidence rates over the past few decades, largely attributed to increasing exposure to ultraviolet (UV) radiation, the major etiologic agent together with genetic predisposition. Indeed, skin cancer formation is the result of the combination of endogenous and environmental factors that can cause DNA damage in healthy cells. Failure to repair these gene alterations can lead to an accumulation of mutations in key cellular regulators, uncontrolled cell differentiation and growth, resulting in skin cancer development.

The recent progress of molecular technologies has opened new avenues in our understanding of signaling pathways underlying skin cancer pathogenesis and identification of biomarkers, useful for skin cancer screening, diagnosis, prognosis and therapy. 

In this Special Issue, research articles, review, hypothesis, communications, opinions, conference reports as well as editorial letters are invited for submission, focusing on the role of diagnostic and prognostic biomarkers and targeted therapies for skin cancers. 

We look forward to receiving your contributions. 

Dr. Claudio Guarneri
Dr. Roberta Giuffrida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • skin cancer
  • melanoma
  • cutaneous squamous cell carcinoma
  • basal cell carcinoma
  • targeted therapy
  • prevention
  • signaling pathway

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

14 pages, 836 KiB  
Review
Basosquamous Carcinoma: Comprehensive Clinical and Histopathological Aspects, Novel Imaging Tools, and Therapeutic Approaches
by Giulia Murgia, Nerina Denaro, Francesca Boggio, Gianluca Nazzaro, Valentina Benzecry, Paolo Bortoluzzi, Emanuela Passoni, Ornella Garrone and Angelo Marzano
Cells 2023, 12(23), 2737; https://doi.org/10.3390/cells12232737 - 30 Nov 2023
Cited by 1 | Viewed by 1177
Abstract
Basosquamous carcinoma (BSC), an uncommon and aggressive nonmelanoma skin cancer exhibiting characteristics ranging from basal cell carcinoma (BCC) to squamous cell carcinoma (SCC), is a subject of controversy in terms of its classification, pathogenesis, histologic morphology, biologic behavior, prognosis, and management. This narrative [...] Read more.
Basosquamous carcinoma (BSC), an uncommon and aggressive nonmelanoma skin cancer exhibiting characteristics ranging from basal cell carcinoma (BCC) to squamous cell carcinoma (SCC), is a subject of controversy in terms of its classification, pathogenesis, histologic morphology, biologic behavior, prognosis, and management. This narrative review is based on an electronic search of English-language articles in PubMed that included the terms “basosquamous carcinoma” and/or “metatypical carcinoma of the skin” in their titles. The review aims to succinctly present and assess current data on the epidemiology, clinical presentation, dermoscopic, LC-OCT, and histopathologic characteristics, as well as the genetics and management of BSC, providing insight into this intriguing entity. As a conclusion, dermoscopy, deep incisional biopsies, and immunohistologic techniques should be applied in clinically suspicious lesions to achieve an early diagnosis and better prognosis of this tumor. Surgical treatments, including wide excision and Mohs’ micrographic surgery, remain the treatment of choice. Finally, Hedgehog pathway inhibitors and checkpoint inhibitors, must be thoroughly investigated with large controlled trials, since they may offer an alternative solution to irresectable or difficult-to-treat locally advanced cases of basosquamous carcinoma. Full article
(This article belongs to the Special Issue Molecular Biomarkers and Signaling Pathways for Skin Cancer Screening, Diagnosis and Therapy)
►▼ Show Figures

Graphical abstract

16 pages, 1589 KiB  
Review
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
by Benedetta Sonego, Adalberto Ibatici, Giulia Rivoli, Emanuele Angelucci, Simona Sola and Cesare Massone
Cells 2023, 12(22), 2656; https://doi.org/10.3390/cells12222656 - 20 Nov 2023
Viewed by 1004
Abstract
In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. [...] Read more.
In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid papulosis; anti-CCR4 (mogamulizumab) in Sezary syndrome; anti-CD123 (tagraxofusp) in blastic plasmocytoid cell neoplasm. Moreover, anti-PD1 (nivolumab), anti-PDL1 (pembrolizumab, atezolizumab), anti-CD52 (alemtuzumab), anti-KIR3DL2-CD158k (lacutamab), and anti-CD70 (cusatuzumab) have been tested or are under investigations in phase II trials. The expression of these epitopes on neoplastic cells in skin biopsies or blood samples plays a central role in the management of PCTCL patients. This narrative review aims to provide readers with an update on the latest advances in the newest therapeutic options for PCTCLs. Full article
(This article belongs to the Special Issue Molecular Biomarkers and Signaling Pathways for Skin Cancer Screening, Diagnosis and Therapy)
►▼ Show Figures

Graphical abstract

18 pages, 1645 KiB  
Review
Signaling Pathways and Therapeutic Strategies in Advanced Basal Cell Carcinoma
by Giulia Vallini, Laura Calabrese, Costanza Canino, Emanuele Trovato, Stefano Gentileschi, Pietro Rubegni and Linda Tognetti
Cells 2023, 12(21), 2534; https://doi.org/10.3390/cells12212534 - 27 Oct 2023
Cited by 1 | Viewed by 1344
Abstract
Non-melanoma skin cancers (NMSCs) are the most common human neoplasms world-wide. In detail, basal cell carcinoma (BCC) is the most frequent malignancy in the fair-skinned population. The incidence of BCC remains difficult to assess due to the poor registration practice; however, it has [...] Read more.
Non-melanoma skin cancers (NMSCs) are the most common human neoplasms world-wide. In detail, basal cell carcinoma (BCC) is the most frequent malignancy in the fair-skinned population. The incidence of BCC remains difficult to assess due to the poor registration practice; however, it has been increasing in the last few years. Approximately, 85% of sporadic BCCs carry mutations in Hedgehog pathway genes, especially in PTCH, SUFU and SMO genes, which lead to the aberrant activation of GLI transcriptional factors, typically silent in cells of adult individuals. The management of advanced BCC (aBCC), both metastatic (mBCC) and locally advanced BCC (laBCC), not candidates for surgical excision or radiotherapy, remains challenging. The discovery of mutations in the Hh signaling pathway has paved the way for the development of Hh pathway inhibiting agents, such as vismodegib and sonidegib, which have represented a breakthrough in the aBCC management. However, the use of these agents is limited by the frequent occurrence of adverse events or the development of drug resistance. In this review, we thoroughly describe the current knowledge regarding the available options for the pharmacological management of aBCCs and provide a forward-looking update on novel therapeutic strategies that could enrich the therapeutic armamentarium of BCC in the near future. Full article
(This article belongs to the Special Issue Molecular Biomarkers and Signaling Pathways for Skin Cancer Screening, Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Other

Jump to: Review

10 pages, 1176 KiB  
Brief Report
A Microenvironment-Related Nine-Gene Signature May Predict Survival in Mycosis Fungoides Patients at Diagnosis
by Silvia Alberti-Violetti, Maria Rosaria Sapienza, Marcello Del Corvo, Federica Melle, Giovanna Motta, Luigia Venegoni, Lorenzo Cerroni, Carlo Cota, Alessandro Pileri, Emilio Berti and Stefano A. Pileri
Cells 2023, 12(15), 1944; https://doi.org/10.3390/cells12151944 - 27 Jul 2023
Cited by 2 | Viewed by 1041
Abstract
Mycosis fungoides (MF) is the most common cutaneous lymphoma characterized by an indolent course. Prognosis is stage-based but this approach does not reflect the different outcomes within stages. Considering that tumor microenvironment is known to be involved in MF pathogenesis and progression, we [...] Read more.
Mycosis fungoides (MF) is the most common cutaneous lymphoma characterized by an indolent course. Prognosis is stage-based but this approach does not reflect the different outcomes within stages. Considering that tumor microenvironment is known to be involved in MF pathogenesis and progression, we decided to investigate 99 MF cases by using the PanCancer Immune Profiling Panel. We identified and validated a signature of 9 genes able to predict MF survival and distinguish a high-risk group with a worse outcome from a low-risk group of cases with a better outcome. At the molecular level, low-risk vs. high-risk cases reported a global upregulation of immune genes, enriched in cytokines, and a higher density of dendritic cells and mast cells, possibly associated with a more favorable clinical course. Full article
(This article belongs to the Special Issue Molecular Biomarkers and Signaling Pathways for Skin Cancer Screening, Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop